Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients

P. Perini, M. Wadhwa, M. Buttarello, A. Meager, A. Facchinetti, R. Thorpe, G. Biasi, P. Gallo

Research output: Contribution to journalArticle

Abstract

We analysed longitudinally the numbers of CD3-CD16+ (natural killer cells, NK) and CD3-CD57+ cells (a subset of NK) in 15 IFNβ1b- and 12 IFNβ1a-treated relapsing-remitting multiple sclerosis (RRMS) patients. IFNβ1b (Betaferon(®))-treated RRMS patients showed a rapid and marked reduction in the number of both NK subsets which started 1 month after therapy initiation, and reached highest significance after 3 months (P=0.000); however, figures reverted to pre-treatment values following the appearance of anti-IFNβ antibodies. In IFNβ1a (Avonex(TM))-treated RRMS patients, the decrease in both CD3-CD16+ and CD3-CD57+ cell number was slower but more persistent; anti-IFNβ antibodies were only rarely detected in these patients, and at lower titers than in IFNβ1b-treated ones. Our findings suggest that NK cells might be one of the major immunological targets of IFNβ-based treatments. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)91-95
Number of pages5
JournalJournal of Neuroimmunology
Volume105
Issue number1
DOIs
Publication statusPublished - Jun 1 2000

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Natural Killer Cells
Multiple Sclerosis
Anti-Idiotypic Antibodies
Therapeutics
Cell Count

Keywords

  • Anti-interferon beta antibodies
  • Interferon beta
  • Multiple sclerosis
  • Natural killer cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Clinical Neurology
  • Neurology

Cite this

Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients. / Perini, P.; Wadhwa, M.; Buttarello, M.; Meager, A.; Facchinetti, A.; Thorpe, R.; Biasi, G.; Gallo, P.

In: Journal of Neuroimmunology, Vol. 105, No. 1, 01.06.2000, p. 91-95.

Research output: Contribution to journalArticle

Perini, P, Wadhwa, M, Buttarello, M, Meager, A, Facchinetti, A, Thorpe, R, Biasi, G & Gallo, P 2000, 'Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients', Journal of Neuroimmunology, vol. 105, no. 1, pp. 91-95. https://doi.org/10.1016/S0165-5728(00)00196-X
Perini, P. ; Wadhwa, M. ; Buttarello, M. ; Meager, A. ; Facchinetti, A. ; Thorpe, R. ; Biasi, G. ; Gallo, P. / Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients. In: Journal of Neuroimmunology. 2000 ; Vol. 105, No. 1. pp. 91-95.
@article{2922d45b65e34da1b2a2b7b9fbacac94,
title = "Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients",
abstract = "We analysed longitudinally the numbers of CD3-CD16+ (natural killer cells, NK) and CD3-CD57+ cells (a subset of NK) in 15 IFNβ1b- and 12 IFNβ1a-treated relapsing-remitting multiple sclerosis (RRMS) patients. IFNβ1b (Betaferon({\circledR}))-treated RRMS patients showed a rapid and marked reduction in the number of both NK subsets which started 1 month after therapy initiation, and reached highest significance after 3 months (P=0.000); however, figures reverted to pre-treatment values following the appearance of anti-IFNβ antibodies. In IFNβ1a (Avonex(TM))-treated RRMS patients, the decrease in both CD3-CD16+ and CD3-CD57+ cell number was slower but more persistent; anti-IFNβ antibodies were only rarely detected in these patients, and at lower titers than in IFNβ1b-treated ones. Our findings suggest that NK cells might be one of the major immunological targets of IFNβ-based treatments. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Anti-interferon beta antibodies, Interferon beta, Multiple sclerosis, Natural killer cells",
author = "P. Perini and M. Wadhwa and M. Buttarello and A. Meager and A. Facchinetti and R. Thorpe and G. Biasi and P. Gallo",
year = "2000",
month = "6",
day = "1",
doi = "10.1016/S0165-5728(00)00196-X",
language = "English",
volume = "105",
pages = "91--95",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1",

}

TY - JOUR

T1 - Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis patients

AU - Perini, P.

AU - Wadhwa, M.

AU - Buttarello, M.

AU - Meager, A.

AU - Facchinetti, A.

AU - Thorpe, R.

AU - Biasi, G.

AU - Gallo, P.

PY - 2000/6/1

Y1 - 2000/6/1

N2 - We analysed longitudinally the numbers of CD3-CD16+ (natural killer cells, NK) and CD3-CD57+ cells (a subset of NK) in 15 IFNβ1b- and 12 IFNβ1a-treated relapsing-remitting multiple sclerosis (RRMS) patients. IFNβ1b (Betaferon(®))-treated RRMS patients showed a rapid and marked reduction in the number of both NK subsets which started 1 month after therapy initiation, and reached highest significance after 3 months (P=0.000); however, figures reverted to pre-treatment values following the appearance of anti-IFNβ antibodies. In IFNβ1a (Avonex(TM))-treated RRMS patients, the decrease in both CD3-CD16+ and CD3-CD57+ cell number was slower but more persistent; anti-IFNβ antibodies were only rarely detected in these patients, and at lower titers than in IFNβ1b-treated ones. Our findings suggest that NK cells might be one of the major immunological targets of IFNβ-based treatments. Copyright (C) 2000 Elsevier Science B.V.

AB - We analysed longitudinally the numbers of CD3-CD16+ (natural killer cells, NK) and CD3-CD57+ cells (a subset of NK) in 15 IFNβ1b- and 12 IFNβ1a-treated relapsing-remitting multiple sclerosis (RRMS) patients. IFNβ1b (Betaferon(®))-treated RRMS patients showed a rapid and marked reduction in the number of both NK subsets which started 1 month after therapy initiation, and reached highest significance after 3 months (P=0.000); however, figures reverted to pre-treatment values following the appearance of anti-IFNβ antibodies. In IFNβ1a (Avonex(TM))-treated RRMS patients, the decrease in both CD3-CD16+ and CD3-CD57+ cell number was slower but more persistent; anti-IFNβ antibodies were only rarely detected in these patients, and at lower titers than in IFNβ1b-treated ones. Our findings suggest that NK cells might be one of the major immunological targets of IFNβ-based treatments. Copyright (C) 2000 Elsevier Science B.V.

KW - Anti-interferon beta antibodies

KW - Interferon beta

KW - Multiple sclerosis

KW - Natural killer cells

UR - http://www.scopus.com/inward/record.url?scp=0034194927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034194927&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(00)00196-X

DO - 10.1016/S0165-5728(00)00196-X

M3 - Article

C2 - 10713368

AN - SCOPUS:0034194927

VL - 105

SP - 91

EP - 95

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1

ER -